News
We send the latest information from SMC Laboratories.
Can-Fite reports on progress with its Namodenoson NASH program
Can-Fite (Israel) reports on 14 December, 2020, on progress with its Namodenoson NASH program. For deta…
CytoDyn announces first patient enrolled in Phase 2 study for NASH
CytoDyn (USA, KY) announced on 2 December, 2020, the first patient first visit metric was met for the Phase 2 …
Inventiva announces FDA has granted Breakthrough Therapy designation to lanifibranor in NASH
Inventiva (France) announced on 12 October, 2020, FDA haas granted Breakthrough Therapy designation to lanifib…
Our clients’ presentations at AASLD ~The Liver Meeting Digital Experience~
Our clients presented data on treatment of NASH using STAMTM model at the AASLD ~The Liver Meeting Digital Exp…
Virginia Comonwealth University's publication in Journal of lipid research
SMC announces that Virginia Commonwealth University (Virginia) has published the results of a study using STAM…
Aldafermin improves fibrosis in patiants with NASH
NGM Biopharmaceuticals, Inc. (USA) presented on August, 2020, the results of the phase 2 trial which met its p…
89bio announces positive topline results from its phase 1b/2a trial of BIO89-100 in NASH
89bio (Israel) announced on 14 September, 2020, positive topline results from its Phase 1b/2a trial with BIO89…
Gilead Sciences, Inc. presented results of the phase 2b ATLAS trial at EASL ~The Digital International Liver Congress™ 2020 ~
Gilead Sciences, Inc. (USA) presented on August, 2020, the results of the phase 2b trial for NASH cirrhosis at…
Galectin Therapeutics announces commencement of patient enrolment of the adaptively-designed Phase 2b/3 trial of Belapectin (GR-MD-02) in NASH cirrhosis
Galectin Therapeutics (USA) announced on June 30, 2020, the commencement of patient enrolment of the adaptivel…
Terns Pharmaceuticals Inc. announced that initiation of patient dosing in the LIFT study, a phase 2A clinical trial of TERN-101 in development for NASH
Terns Pharmaceuticals Inc. (USA and Shanghai) announced on 23 July, 2020, the initiation of patient dosing in …